Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells

Zhao,Bing; Hu,Mengcai

doi:10.3892/ol.2013.1632

Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells

Authors:
- Bing Zhao
- Mengcai Hu
View Affiliations

Affiliations: Department of Health, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: October 15, 2013 https://doi.org/10.3892/ol.2013.1632
Pages: 1749-1755

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gallic acid is a trihydroxybenzoic acid, also known as 3,4,5‑trihydroxybenzoic acid, which is present in plants worldwide, including Chinese medicinal herbs. Gallic acid has been shown to have cytotoxic effects in certain cancer cells, without damaging normal cells. The objective of the present study was to determine whether gallic acid is able to inhibit human cervical cancer cell viability, proliferation and invasion and suppress cervical cancer cell‑mediated angiogenesis. Treatment of HeLa and HTB‑35 human cancer cells with gallic acid decreased cell viability in a dose‑dependent manner. BrdU proliferation and tube formation assays indicated that gallic acid significantly decreased human cervical cancer cell proliferation and tube formation in human umbilical vein endothelial cells, respectively. Additionally, gallic acid decreased HeLa and HTB‑35 cell invasion in vitro. Western blot analysis demonstrated that the expression of ADAM17, EGFR, p‑Akt and p‑Erk was suppressed by gallic acid in the HeLa and HTB‑35 cell lines. These data indicate that the suppression of ADAM17 and the downregulation of the EGFR, Akt/p‑Akt and Erk/p‑Erk signaling pathways may contribute to the suppression of cancer progression by Gallic acid. Gallic acid may be a valuable candidate for the treatment of cervical cancer.

View Figures

View References

1	Armstrong EP: Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 16:217–230. 2010.PubMed/NCBI
2	Globocan. 2008, IARC. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#WOMEN. Accessed September 20, 2013
3	Alvarez-Salas LM and DiPaolo JA: Molecular approaches to cervical cancer therapy. Curr Drug Discov Technol. 4:208–219. 2007. View Article : Google Scholar : PubMed/NCBI
4	Haroon S and Cui M: Role of Pap smear in early diagnosis of cervical cancer - A case study of women in Saudi Arabia. Life Science Journal. 9:1027–1036. 2012.
5	Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Suppression of human cervical cancer cell lines Hela and DoTc2 4510 by a mixture of lysine, proline, ascorbic acid, and green tea extract. Int J Gynecol Cancer. 16:1241–1247. 2006. View Article : Google Scholar : PubMed/NCBI
6	Faried A, Kurnia D, Faried LS, et al: Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int J Oncol. 30:605–613. 2007.PubMed/NCBI
7	Raina K, Rajamanickam S, Deep G, Singh M, Agarwal R and Agarwal C: Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. Mol Cancer Ther. 7:1258–1267. 2008. View Article : Google Scholar : PubMed/NCBI
8	You BR and Park WH: Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase. Toxicol In Vitro. 24:1356–1362. 2010. View Article : Google Scholar : PubMed/NCBI
9	You BR, Kim SZ, Kim SH and Park WH: Gallic acid-induced lung cancer cell death is accompanied by ROS increase and glutathione depletion. Mol Cell Biochem. 357:295–303. 2011. View Article : Google Scholar : PubMed/NCBI
10	Verma S, Singh A and Mishra A: Gallic acid: Molecular rival of cancer. Environ Toxicol Pharmacol. 35:473–485. 2013. View Article : Google Scholar : PubMed/NCBI
11	You BR, Moon HJ, Han YH and Park WH: Gallic acid inhibits the growth of HeLa cervical cancer cells via apoptosis and/or necrosis. Food Chem Toxicol. 48:1334–1340. 2010. View Article : Google Scholar : PubMed/NCBI
12	Skehan P, Storeng R, Scudiero D, et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
13	Agarwal C, Tyagi A and Agarwal R: Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther. 5:3294–3302. 2006. View Article : Google Scholar
14	Zhai Y, Bommer GT, Feng Y, Wiese AB, Fearon ER and Cho KR: Loss of estrogen receptor 1 enhances cervical cancer invasion. Am J Pathol. 177:884–895. 2010. View Article : Google Scholar : PubMed/NCBI
15	Di Leo S, Caschetto S, Garozzo G, et al: Angiogenesis as a prognostic factor in cervical carcinoma. Eur J Gynaecol Oncol. 19:158–162. 1998.
16	Triratanachat S, Niruthisard S, Trivijitsilp P, Tresukosol D and Jarurak N: Angiogenesis in cervical intraepithelial neoplasia and early-staged uterine cervical squamous cell carcinoma: clinical significance. Int J Gynecol Cancer. 16:575–580. 2006. View Article : Google Scholar
17	Lin P, Sun X, Feng T, et al: ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol Cell Biochem. 359:235–243. 2012. View Article : Google Scholar : PubMed/NCBI
18	Xiao LJ, Lin P, Lin F, et al: ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol. 40:1714–1724. 2012.PubMed/NCBI
19	Jeong JH, Jeong YJ, Cho HJ, et al: Ascochlorin inhibits growth factor-induced HIF-1α activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells. J Cell Biochem. 113:1302–1313. 2012.PubMed/NCBI
20	Mathur SP, Mathur RS and Young RC: Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Immunol. 44:222–230. 2000. View Article : Google Scholar : PubMed/NCBI
21	Lakshmi S, Nair M, Jayaprakash P and Pillai M: Epidermal growth factor and its receptor in cervical cancer. Oncol Rep. 4:1103–1106. 1997.PubMed/NCBI
22	Gaffney DK, Haslam D, Tsodikov A, et al: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 56:922–928. 2003. View Article : Google Scholar
23	Madlener S, Illmer C, Horvath Z, et al: Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. Cancer Lett. 245:156–162. 2007. View Article : Google Scholar : PubMed/NCBI
24	Hawighorst H, Knapstein PG, Weikel W, et al: Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res. 57:4777–4786. 1997.
25	Liu Z, Schwimer J, Liu D, et al: Gallic acid is partially responsible for the antiangiogenic activities of Rubus leaf extract. Phytother Res. 20:806–813. 2006. View Article : Google Scholar : PubMed/NCBI
26	Soonthornthum T, Arias-Pulido H, Joste N, et al: Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol. 22:2166–2178. 2011. View Article : Google Scholar : PubMed/NCBI
27	Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 7(Suppl 4): 2–8. 2002. View Article : Google Scholar : PubMed/NCBI
28	Lu X, Lu D, Scully M and Kakkar V: ADAM proteins - therapeutic potential in cancer. Curr Cancer Drug Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
29	Kheradmand F and Werb Z: Shedding light on sheddases: role in growth and development. Bioessays. 24:8–12. 2002. View Article : Google Scholar : PubMed/NCBI
30	Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther. 8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI